IVIRMA, 28023 Madrid, Spain.
Departamento de Biomedicina y Biotecnología, Universidad de Alcalá de Henares, 28023 Madrid, Spain.
Nutrients. 2022 Apr 27;14(9):1820. doi: 10.3390/nu14091820.
Currently, there is abundant scientific evidence showing that the vitamin D endocrine system (VDES) is a highly complex endocrine system with multiple actions in different regions of the body. The unequivocal presence of vitamin D receptors in different tissues related to fertility, and to specific aspects of women's health such as pregnancy, undoubtedly implies functions of this steroid hormone in both male and female fertility and establishes relationships with different outcomes of human gestation. In order to review the role of the VDES in human fertility, we evaluated the relationships established between 25-hydroxyvitamin D (calcifediol) deficiency and in vitro fertilization, as well as aspects related to ovarian reserve and fertility, and commonly diagnosed endocrinopathies such as polycystic ovary disease. Likewise, we briefly reviewed the relationships between calcifediol deficiency and uterine fibroids, as well as the role that treatment may have in improving human fertility. Finally, the best scientific evidence available on the consequences of calcifediol deficiency during pregnancy is reviewed in relation to those aspects that have accumulated the most scientific literature to date, such as the relationship with the weight of the newborn at the time of delivery, the appearance of preeclampsia, and the risk of developing gestational diabetes and its final consequences for the pregnancy. To date, there is no definitive consensus on the necessary dose for treatment of calcifediol deficiency in the therapeutic management of infertility or during pregnancy. Large prospective clinical intervention studies are needed to clarify the benefits associated with this supplementation and the optimal dose to use in each situation. Although most intervention studies to date have been conducted with cholecalciferol, due to its much longer history of use in daily care, the use of calcifediol to alleviate 25-hydroxyvitamin D deficiency seems safe, even during pregnancy. The unequivocal presence of vitamin D receptors in very different tissues related to human fertility, both male and female, as well as in structures typical of pregnancy, allows us to investigate the crucial role that this steroid hormone has in specific aspects of women's health, such as pregnancy and the ability to conceive. Well-designed clinical studies are needed to elucidate the necessary dose and the best form of treatment to resolve the very common calcifediol deficiency in women of reproductive age.
目前,有大量科学证据表明,维生素 D 内分泌系统(VDES)是一个高度复杂的内分泌系统,在身体的不同区域具有多种作用。维生素 D 受体在与生育有关的不同组织以及与女性健康的特定方面(如妊娠)中明确存在,这无疑意味着这种类固醇激素在男性和女性生育能力中具有功能,并与人类妊娠的不同结果建立了关系。为了综述 VDES 在人类生育能力中的作用,我们评估了 25-羟维生素 D(钙二醇)缺乏与体外受精之间的关系,以及与卵巢储备和生育能力相关的方面,以及常见的内分泌疾病,如多囊卵巢疾病。同样,我们简要综述了钙二醇缺乏与子宫肌瘤之间的关系,以及治疗可能在改善人类生育能力方面的作用。最后,综述了在妊娠期间钙二醇缺乏的后果方面可获得的最佳科学证据,以及与迄今为止积累了最多科学文献的方面的关系,例如与分娩时新生儿体重的关系、子痫前期的出现、妊娠期糖尿病的风险及其对妊娠的最终后果。迄今为止,在治疗不孕症或妊娠期间钙二醇缺乏的治疗管理方面,还没有关于必要剂量的明确共识。需要进行大型前瞻性临床干预研究,以阐明这种补充的益处以及在每种情况下使用的最佳剂量。尽管迄今为止大多数干预研究都是用胆钙化醇进行的,因为它在日常护理中的使用历史更长,但使用钙二醇来缓解 25-羟维生素 D 缺乏似乎是安全的,即使在怀孕期间也是如此。维生素 D 受体在与人类生育能力相关的非常不同的组织中明确存在,无论是男性还是女性,以及在妊娠的典型结构中也明确存在,这使我们能够研究这种类固醇激素在女性健康的特定方面(如妊娠和受孕能力)中具有的关键作用。需要进行精心设计的临床研究,以阐明解决育龄妇女中非常常见的钙二醇缺乏症所需的剂量和最佳治疗形式。